Literature DB >> 31505312

Testosterone treatment and association with thrombin generation and coagulation inhibition in Klinefelter syndrome: A cross-sectional study.

Simon Chang1, Daniel Biltoft2, Anne Skakkebæk3, Jens Fedder4, Anders Bojesen5, M Vakur Bor2, Claus H Gravholt6, Anna-Marie B Münster2.   

Abstract

BACKGROUND: The background for the increased occurrence of thrombosis seen in Klinefelter syndrome (KS) is unknown. The aim was to compare thrombin generation and coagulation inhibition between men with KS and controls, and to investigate whether coagulation in KS was associated with testosterone treatment (TT), and as such, measures of androgen action.
METHODS: Untreated men with KS (U-KS) or testosterone treated men with KS (T-KS) were included. KS groups were matched by age and education to groups of control males with no history of TT. Blood samples were collected after overnight fasting. Low tissue factor (1pM) thrombin generation was expressed as lag time (min), time to peak (min), peak (nmol/L), and endogenous thrombin potential (nmol/L × min, ETP). Coagulation inhibitors, sex hormones, and haematocrit were measured. Matched groups were compared by Student's t-test or Wilcoxon rank sum test. Among KS, TT status as an outcome predictor was evaluated by linear regression.
RESULTS: 18 U-KS and 27 T-KS with corresponding controls participated. Thrombin generation was not different comparing U-KS and T-KS with respective control groups. Among KS, ETP was lower in T-KS compared with U-KS and inversely associated with testosterone, LH-testosterone ratio and haematocrit.
CONCLUSION: Neither U-KS nor T-KS expressed a pro-coagulant state compared with controls. Thrombin generation among KS was inversely associated with androgen action and lower in T-KS compared with U-KS. Whether TT is capable of lowering thrombotic risk among men with KS needs to be assessed prospectively.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31505312     DOI: 10.1016/j.thromres.2019.08.011

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

Review 1.  Morbidity in Klinefelter syndrome and the effect of testosterone treatment.

Authors:  Simon Chang; Anne Skakkebaek; Shanlee M Davis; Claus H Gravholt
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-06-04       Impact factor: 3.908

Review 2.  Relationships between endogenous and exogenous testosterone and cardiovascular disease in men.

Authors:  Arthi Thirumalai; Bradley D Anawalt
Journal:  Rev Endocr Metab Disord       Date:  2022-10-11       Impact factor: 9.306

3.  Reduced fibrin clot lysis in Klinefelter syndrome associated with hypogonadism.

Authors:  Simon Chang; Arkadiusz J Goszczak; Anne Skakkebæk; Jens Fedder; Anders Bojesen; M Vakur Bor; Moniek P M de Maat; Claus H Gravholt; Anna-Marie B Münster
Journal:  Endocr Connect       Date:  2022-05-10       Impact factor: 3.221

4.  Evaluation of the Efficacy of Transdermal and Injection Testosterone Therapy in Klinefelter Syndrome: A Real-Life Study.

Authors:  Apiraa Kabilan; Anne Skakkebæk; Simon Chang; Claus H Gravholt
Journal:  J Endocr Soc       Date:  2021-04-05

5.  Klinefelter syndrome and testosterone treatment: a national cohort study on thrombosis risk.

Authors:  Simon Chang; Christian Fynbo Christiansen; Anders Bojesen; Svend Juul; Anna-Marie B Münster; Claus H Gravholt
Journal:  Endocr Connect       Date:  2020-01       Impact factor: 3.335

6.  Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry.

Authors:  Rita Indirli; Emanuele Ferrante; Erica Scalambrino; Eriselda Profka; Marigrazia Clerici; Tommaso Lettera; Andreea Liliana Serban; Walter Vena; Alessandro Pizzocaro; Marco Bonomi; Biagio Cangiano; Giulia Carosi; Gherardo Mazziotti; Luca Persani; Andrea Lania; Maura Arosio; Flora Peyvandi; Giovanna Mantovani; Armando Tripodi
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.